With $850 million in dry powder to deploy from its second US dollar-denominated fund, China’s Genesis Capital is targeting Series C and D rounds for start-ups on the cusp of greatness
Genesis Capital’s sweet spot is defined by timing, as well as by industry and size: the Chinese growth-stage investor wants to back technology-enabled companies after their products are proven but before...
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.